A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies

BACKGROUND: Heat-shock protein 990 (HSP990) is a potent and selective synthetic small-molecule HSP90 inhibitor. The primary objectives of this phase I first-in-human study were to determine dose-limiting toxicities (DLTs), maximum-tolerated dose (MTD) and recommended phase II dose (RP2D). Secondary...

Descripción completa

Detalles Bibliográficos
Autores principales: Spreafico, A, Delord, J-P, De Mattos-Arruda, L, Berge, Y, Rodon, J, Cottura, E, Bedard, P L, Akimov, M, Lu, H, Pain, S, Kaag, A, Siu, L L, Cortes, J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4333497/
https://www.ncbi.nlm.nih.gov/pubmed/25625276
http://dx.doi.org/10.1038/bjc.2014.653

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4333497/
https://www.ncbi.nlm.nih.gov/pubmed/25625276
http://dx.doi.org/10.1038/bjc.2014.653

Ejemplares similares